Algernon Pharmaceuticals Stock Debt To Equity
| AGNPF Stock | USD 0.05 0 5.11% |
Algernon Pharmaceuticals fundamentals help investors to digest information that contributes to Algernon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Algernon OTC Stock. The fundamental analysis module provides a way to measure Algernon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Algernon Pharmaceuticals otc stock.
Algernon |
Algernon Pharmaceuticals OTC Stock Debt To Equity Analysis
Algernon Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Algernon Pharmaceuticals has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The debt to equity for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
| All Next | Launch Module |
Algernon Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.53 | |||
| Current Valuation | 3.03 M | |||
| Shares Outstanding | 2.41 M | |||
| Shares Owned By Insiders | 1.70 % | |||
| Shares Owned By Institutions | 14.73 % | |||
| Price To Book | 1.02 X | |||
| EBITDA | (6.02 M) | |||
| Net Income | (6.05 M) | |||
| Cash And Equivalents | 872.84 K | |||
| Cash Per Share | 0.44 X | |||
| Current Ratio | 1.16 X | |||
| Book Value Per Share | 1.86 X | |||
| Cash Flow From Operations | (2.91 M) | |||
| Earnings Per Share | (2.28) X | |||
| Beta | 0.32 | |||
| Market Capitalization | 3.96 M | |||
| Total Asset | 8.14 M | |||
| Net Asset | 8.14 M |
About Algernon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Algernon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Algernon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Algernon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Algernon OTC Stock
Algernon Pharmaceuticals financial ratios help investors to determine whether Algernon OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Algernon with respect to the benefits of owning Algernon Pharmaceuticals security.